FindTrial
Sign In

VCN-01

GENETIC8 trials

Sponsors

Theriva Biologics S.L., Theriva Biologics SL, Fundació Sant Joan de Déu, Institut Català d'Oncologia, University of Pennsylvania

Conditions

Carcinoma, Squamous Cell of Head and NeckHead and Neck NeoplasmsLocally Advanced Solid TumorsMetastasisMetastaticMetastatic Pancreatic AdenocarcinomaMetastatic Pancreatic CancerMetastatic Solid Tumors

Phase 1

A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
CompletedNCT02045589
Theriva Biologics SLMetastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
Start: 2014-01-31End: 2018-09-30Updated: 2018-10-01
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
CompletedNCT02045602
Theriva Biologics SLLocally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma
Start: 2014-01-31End: 2020-01-31Updated: 2020-10-08
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
NCT03799744
Institut Català d'OncologiaCarcinoma, Squamous Cell of Head and Neck, Head and Neck Neoplasms, Metastasis +1
Start: 2019-03-20End: 2023-01-31Updated: 2022-03-28
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Active, not recruitingNCT05057715
University of PennsylvaniaPancreatic Cancer, Serous Ovarian Cancer
Start: 2022-03-02End: 2038-09-01Updated: 2026-07-13

Phase 2

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
CompletedNCT05673811
Theriva Biologics SLMetastatic, Pancreatic Adenocarcinoma
Start: 2023-01-10End: 2025-03-28Updated: 2025-04-16
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)
CompletedCTIS2024-511290-30-00
Theriva Biologics S.L.Metastatic Pancreatic Cancer
Start: 2022-11-15End: 2025-03-28Target: 92Updated: 2024-11-21
A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)
Not yet recruitingCTIS2026-525566-21-00
Theriva Biologics S.L.metastatic pancreatic adecarcinoma
Target: 6Updated: 2026-06-30

Unknown Phase

Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma
CompletedNCT03284268
Fundació Sant Joan de DéuRetinoblastoma, Recurrent
Start: 2017-09-06End: 2024-06-14Updated: 2024-08-27

Related Papers

A phase I dose-escalation study to assess the oncolytic virus VCN-01 safety and efficacy in refractory retinoblastoma patients.
Journal of Clinical Oncology2025-05-28
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.
2024-11-0610 citations
VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.
Journal of Clinical Oncology2024-06-011 citations
671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer
Regular and Young Investigator Award Abstracts2023-10-311 citations
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer2022-03-0174 citations
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
Journal for ImmunoTherapy of Cancer2021-11-0180 citations